医学
以兹提米比
不利影响
安全概况
前蛋白转化酶
加药
可欣
PCSK9
药理学
内科学
重症监护医学
他汀类
低密度脂蛋白受体
胆固醇
生物信息学
脂蛋白
生物
作者
Ahmed A. Mohamed,Kausik K. Ray
出处
期刊:Current Opinion in Cardiology
[Ovid Technologies (Wolters Kluwer)]
日期:2023-07-26
卷期号:38 (6): 527-532
被引量:1
标识
DOI:10.1097/hco.0000000000001074
摘要
This review aims to offer an up-to-date evaluation of Inclisiran's (a small interfering RNA treatment) ability to decrease low-density lipoprotein cholesterol (LDL-C), as well as its safety and potential effects on decreasing cardiovascular risk.Inclisiran significantly lowers LDL-C levels, as shown by phase III studies, by inhibiting hepatic synthesis of proprotein convertase subtilisin kexin 9 (PCSK-9), a protein implicated in the degradation of LDL receptors. Inclisiran has the benefit of subcutaneous injection twice a year, which may reduce patient nonadherence when compared with other LDL-C reducing therapies such as statins and ezetimibe, which require daily dosing. When added on top of statins, a greater proportion of patients achieved recommended cholesterol goals. It has also demonstrated a good safety profile with few adverse effects.Inclisiran is a promising treatment for lowering LDL-C levels in people at high risk of atherosclerotic cardiovascular disease. It is a practical and well tolerated option for those who struggle to stick to medication regimes because of its twice-yearly dosage schedule and a good safety profile. Although it has been demonstrated to be effective in decreasing LDL-C, further research is needed to determine its impact on reducing cardiovascular events. Nonetheless, Inclisiran is a significant advancement in lipid-lowering medication and could improve patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI